Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? (Q38886698)

7 September 2017

1 reference

title

Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines? (English)

1 reference

7 September 2017

Sharan Bobbala

1

1 reference

PubMed ID

27380191

7 September 2017

Sarah Hook

series ordinal

2

1 reference

7 September 2017

5 July 2016

1 reference

7 September 2017

Pharmaceutical Research

1 reference

7 September 2017

33

1 reference

7 September 2017

2078-2097

1 reference

7 September 2017

9

1 reference

A brief history of vaccines and vaccination

7 September 2017

2 references

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

21 January 2018

12 December 2020

A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Designing tomorrow's vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

New horizons in adjuvants for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Mechanisms of action of adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

New paradigms for HIV/AIDS vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Profiling the host response to malaria vaccination and malaria challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

TB vaccines: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cross-presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanoparticle clearance is governed by Th1/Th2 immunity and strain background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Emulsion-based adjuvants for influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Adjuvants for malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Receptor-specific delivery of protein antigen to dendritic cells by a nanoemulsion formed using top-down non-covalent click self-assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Vaccine adjuvants: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Towards an understanding of the adjuvant action of aluminium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Alum adjuvant: some of the tricks of the oldest adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Liposomal vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Materials innovation for co-delivery of diverse therapeutic cargos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

The experimental design as practical approach to develop and optimize a formulation of peptide-loaded liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Chemical stability of liposomes: implications for their physical stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Liposomes as nanomedical devices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Liposomes as vaccine delivery systems: a review of the recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Biomaterials for nanoparticle vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Efficiency of pH-sensitive fusogenic polymer-modified liposomes as a vaccine carrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Current status and potential application of ISCOMs in veterinary medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

ISCOM-based vaccines: the second decade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM? vaccines and conventional vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

In vivo activity of cationic immune stimulating complexes (PLUSCOMs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cationic cage-like complexes formed by DC-cholesterol, Quil-A, and phospholipid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immune response of heifers against a Staphylococcus aureus CP5 whole cell and lysate vaccine formulated with ISCOM Matrix adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Recent trends in vaccine delivery systems: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Enhanced loading of water-soluble actives into bicontinuous cubic phase liquid crystals using cationic surfactants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Docetaxel-Loaded Fluorescent Liquid-Crystalline Nanoparticles for Cancer Theranostics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid A stimulate robust cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Influenza virosomes as vaccine adjuvant and carrier system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Biosynthesis of archaeal membrane ether lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

New generation of liposomes called archaeosomes based on natural or synthetic archaeal lipids as innovative formulations for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Archaeosomes varying in lipid composition differ in receptor-mediated endocytosis and differentially adjuvant immune responses to entrapped antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Archaeosomes as adjuvants for combination vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Archaeal lipid mucosal vaccine adjuvant and delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

PLGA-based nanoparticles: an overview of biomedical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Chitosan-based systems for the delivery of vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Chitosan-based delivery systems for protein therapeutics and antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Towards designer microparticles: simultaneous control of anisotropy, shape, and size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Peptide/protein vaccine delivery system based on PLGA particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanoparticle delivery systems in cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Multifunctional nanocarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Synthetic Nanoparticles for Vaccines and Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Programming the magnitude and persistence of antibody responses with innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Micelle-Based Adjuvants for Subunit Vaccine Delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Cationic micelle based vaccine induced potent humoral immune response through enhancing antigen uptake and formation of germinal center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Synthesis, characterization and evaluation of novel triblock copolymer based nanoparticles for vaccine delivery against hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Design and Development of Immunomodulatory Antigen Delivery Systems Based on Peptide/PEG-PLA Conjugate for Tuning Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Preparation and in vitro evaluation of imiquimod loaded polylactide-based micelles as potential vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Structure-based programming of lymph-node targeting in molecular vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Bioengineering virus-like particles as vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Virus-like particles in vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Antigen delivery by virus-like particles for immunotherapeutic vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

The Bacterial Ghost platform system: production and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Bacterial ghosts as adjuvant particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Helicobacter pylori outer inflammatory protein DNA vaccine-loaded bacterial ghost enhances immune protective efficacy in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Generation of a safety enhanced Salmonella Gallinarum ghost using antibiotic resistance free plasmid and its potential as an effective inactivated vaccine candidate against fowl typhoid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Single-injection vaccines: Progress, challenges, and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Hydrogel scaffolds for tissue engineering: Progress and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Hydrogels for pharmaceutical and biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Injectable biodegradable hydrogels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A review of poloxamer 407 pharmaceutical and pharmacological characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Thermoresponsive hydrogels in biomedical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

In vitro and in vivo investigation of thermosensitive chitosan hydrogels containing silica nanoparticles for vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Continuous antigen delivery from controlled release implants induces significant and anamnestic immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Lipidic implants for controlled release of bioactive insulin: effects on cartilage engineered in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Protein and Peptide drug delivery: oral approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

The importance of injecting vaccines into muscle. Different patients need different needle sizes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Intradermal delivery for vaccine dose sparing: overview of current issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Differences in efficiency, satisfaction and adverse events between self-administered intradermal and nurse-administered intramuscular influenza vaccines in hospital workers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Intralymphatic immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Adjuvant effect of cationic liposomes and CpG depends on administration route.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immunomodulation of gut-associated lymphoid tissue: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Recent progress in mucosal vaccine development: potential and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Delivery strategies to enhance oral vaccination against enteric infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A lipid based multi-compartmental system: Liposomes-in-double emulsion for oral vaccine delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Plant-made oral vaccines against human infectious diseases-Are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Mucosa-associated lymphoid tissues as sites for uptake, carriage and excretion of tubercle bacilli and other pathogenic mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Towards tailored vaccine delivery: needs, challenges and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanotechnology solutions for mucosal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Mannan-decorated thiolated Eudragit microspheres for targeting antigen presenting cells via nasal vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Devices and formulations for pulmonary vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanotechnology approaches for inhalation treatment of lung diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nasal and pulmonary vaccine delivery using particulate carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

New insights in mucosal vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Transcutaneous antigen delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

In vivo function of Langerhans cells and dermal dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Liposomes and skin: from drug delivery to model membranes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Ethosomes - novel vesicular carriers for enhanced delivery: characterization and skin penetration properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Nanoparticles for transcutaneous vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Antigen-loaded nanocarriers enhance the migration of stimulated Langerhans cells to draining lymph nodes and induce effective transcutaneous immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Transcutaneous vaccines--current and emerging strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Transcutaneous immunisation assisted by low-frequency ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Induction of cytotoxic T-lymphocytes by electroporation-enhanced needle-free skin immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Recent insights into cutaneous immunization: How to vaccinate via the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Laser-assisted intradermal delivery of adjuvant-free vaccines targeting XCR1+ dendritic cells induces potent antitumoral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Microneedles for drug and vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Rapid intradermal delivery of liquid formulations using a hollow microstructured array

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Low temperature fabrication of biodegradable sugar glass microneedles for transdermal drug delivery applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Implantable silk composite microneedles for programmable vaccine release kinetics and enhanced immunogenicity in transcutaneous immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Activation of the NLRP3 inflammasome is not a feature of all particulate vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Advances in Lipid-Based Subunit Vaccine Formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Modified thermoresponsive Poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immunostimulatory biodegradable implants containing the adjuvant Quil-A—Part II:In vivoevaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Immunostimulatory biodegradable implants containing the adjuvant Quil-A—Part I: Physicochemical characterisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Transcutaneous immunization using microneedles and cubosomes: Mechanistic investigations using Optical Coherence Tomography and Two-Photon Microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-016-1979-0

Intra-lymph node injection of biodegradable polymer particles

21 January 2018

1 reference

12 December 2020

Cancer vaccines: on the threshold of success

1 reference

12 December 2020

Influence of Quil A on liposomal membranes

1 reference

12 December 2020

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.

1 reference

12 December 2020

The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep

1 reference

12 December 2020

Optimizing Druggability through Liposomal Formulations: New Approaches to an Old Concept

1 reference

12 December 2020

Methods for in vitro percutaneous absorption studies. II. Animal models for human skin

1 reference

12 December 2020

Effective transcutaneous immunization by antigen-loaded flexible liposome in vivo

1 reference

12 December 2020

First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice

1 reference

12 December 2020

Alum adjuvanticity: unraveling a century old mystery

1 reference

12 December 2020

Impact of implant composition of twin-screw extruded lipid implants on the release behavior

1 reference

12 December 2020

Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen

1 reference

12 December 2020

Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration

1 reference

12 December 2020

Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology

1 reference

12 December 2020

Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient

1 reference

12 December 2020

In vivo investigation of twin-screw extruded lipid implants for vaccine delivery

1 reference

12 December 2020

Intralymphatic immunotherapy and vaccination in mice

1 reference

12 December 2020

A review of clinical trials of human papillomavirus prophylactic vaccines

1 reference

12 December 2020

Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine: enhancement of mucosal and systemic immune response

1 reference

12 December 2020

Cubic and hexagonal liquid crystals as drug delivery systems

1 reference

12 December 2020

PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity

1 reference

12 December 2020

Recent advances of chitosan nanoparticles as drug carriers

1 reference

12 December 2020

Novel adjuvants & delivery vehicles for vaccines development: a road ahead

1 reference

12 December 2020

Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles

1 reference

12 December 2020

10.1007/S11095-016-1979-0

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27380191